Phase II trial of atezolizumab (Anti-PD-L1) in the treatment of relapsed/refractory IIB/IVB mycosis fungoides/Sézary syndrome patients after previous systemic treatment. EORTC-1652-CLTG “PARCT”
Atezolizumab shows moderate activity in pretreated refractory/relapsed MF and SS. Further studies are needed to identify reliable predictors of safety and treatment response.
Authors
- Rudolf Stadler (ORCID: https://orcid.org/0000-0003-2683-6028)
- José Casas-Martín (ORCID: https://orcid.org/0000-0001-6962-8697)
- Paul Moss (ORCID: https://orcid.org/0000-0002-6895-1967)
- Gabriele Roccuzzo (ORCID: https://orcid.org/0000-0001-7126-5506)
- Jammbe Musoro (ORCID: https://orcid.org/0000-0002-6228-3531)
- Delphine Sartori
- Robert Knobler (ORCID: https://orcid.org/0000-0002-7380-7062)
- Pablo L. Ortiz‐Romero (ORCID: https://orcid.org/0000-0003-2985-9639)
- Duncan Murray (ORCID: https://orcid.org/0000-0003-4664-3725)
- René Stranzenbach (ORCID: https://orcid.org/0000-0003-1882-4908)
- Sandrine Marréaud (ORCID: https://orcid.org/0000-0002-3205-3858)
- Pietro Quaglino (ORCID: https://orcid.org/0000-0003-4185-9586)
- Evangelia Papadavid (ORCID: https://orcid.org/0000-0002-8634-102X)
- Rein Willemze (ORCID: https://orcid.org/0000-0002-4561-7616)
- Emmanuella Guenova (ORCID: https://orcid.org/0000-0001-5478-8735)
- Julia Scarisbrick (ORCID: https://orcid.org/0000-0002-8011-4408)
- Samantha Drennan (ORCID: https://orcid.org/0000-0002-8993-7806)
- Maxime Battistella (ORCID: https://orcid.org/0000-0002-7053-7431)
- Constanze Jonak (ORCID: https://orcid.org/0000-0002-2347-436X)
- Martine Bagot
- Jimmy Van Hear
Institutions
- Inserm (FR)
- National and Kapodistrian University of Athens (GR)
- Université Paris Cité (FR)
- University Hospitals of the Ruhr-University of Bochum (DE)
- Leiden University Medical Center (NL)
- University Hospitals Coventry and Warwickshire NHS Trust (GB)
- Research Institute Hospital 12 de Octubre (ES)
- Assistance Publique – Hôpitaux de Paris (FR)
- Hospital Universitario 12 De Octubre (ES)
- European Organisation for Research and Treatment of Cancer (BE)
- Department of Medical Sciences (BY)
- NIHR Surgical Reconstruction and Microbiology Research Centre (GB)
- St. Josef-Hospital (DE)
- Immune Regulation (United Kingdom) (GB)
- Hôpital Saint-Louis (FR)
- University of Turin (IT)
- Medical University of Vienna (AT)
- Ruhr University Bochum (DE)
- University of Lausanne (CH)
Publication Details
- Journal
- European Journal of Cancer
- Published
- 2025-04-29
- DOI
- https://doi.org/10.1016/j.ejca.2025.115484
- Citations
- 5
- Primary Topic
- Cutaneous lymphoproliferative disorders research
- Type
- article
- Field-Weighted Citation Impact
- 10.02
Funders
- Roche
- F. Hoffmann-La Roche